Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …

Aims Tocilizumab has emerged as an important therapy in treating patients with coronavirus
disease (COVID‐19). Our purpose was to evaluate the efficacy and safety of tocilizumab …

Objective: This review was performed to compare the efficacy and safety among hospitalized
patients with COVID-19 who received baricitinib and those who received tocilizumab …

Background A recent prospective meta-analysis demonstrated that interleukin-6 antagonists
are associated with lower all-cause mortality in hospitalised patients with COVID-19 …

Purpose COVID-19 is characterized by dysregulated immune response, respiratory failure
and a relevant mortality rate among hospitalized patients. Interleukin-6 (IL-6) is involved in …

Background Coronavirus disease (COVID‐19), an infectious disease caused by the novel
coronavirus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has spread …

Background The coronavirus disease 2019 (COVID‐19) has spread worldwide since early
2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines …

Abstract Background Randomised Evaluation of COVID-19 Therapy (RECOVERY)
demonstrated that tocilizumab reduces mortality in hospitalized COVID-19 patients …

Цель обзора-анализ опубликованных данных научных статей о лекарственных
средствах, указанных как этиотропные и разрешенные для амбулаторного …

BACKGROUND In patients infected with SARS-CoV-2, disease severity and outcomes are
related to the characteristics of the immune response. 1-6 The median time from onset of …